1. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013; 31:3997–4013. PMID:
24101045.
Article
2. Kim S, Park HS, Kim JY, Ryu J, Park S, Kim SI. Comparisons of oncologic outcomes between triple-negative breast cancer (TNBC) and non-TNBC among patients treated with breast-conserving therapy. Yonsei Med J. 2016; 57:1192–1198. PMID:
27401651.
Article
3. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 1999; 21:309–318. PMID:
10211534.
Article
4. Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007; 357:39–51. PMID:
17611206.
5. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics. 2004; 3:379–398. PMID:
14762215.
6. Dobson L, Conway C, Hanley A, Johnson A, Costello S, O'Grady A, et al. Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation. Histopathology. 2010; 57:27–38. PMID:
20584089.
Article
7. Helin HO, Tuominen VJ, Ylinen O, Helin HJ, Isola J. Free digital image analysis software helps to resolve equivocal scores in HER2 immunohistochemistry. Virchows Arch. 2016; 468:191–198. PMID:
26493985.
Article
8. Minot DM, Voss J, Rademacher S, Lwin T, Orsulak J, Caron B, et al. Image analysis of HER2 immunohistochemical staining. Reproducibility and concordance with fluorescence in situ hybridization of a laboratory-validated scoring technique. Am J Clin Pathol. 2012; 137:270–276. PMID:
22261453.